Floatz logo

Pyrotinib

Refractory Diffuse Large B-cell Lymphoma

BeiGeneSmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
81/ 100

Competitive context

5 Active assets in the Refractory Diffuse Large B-cell Lymphoma cohort.

Asset / SponsorPhaseRating
ADENOSINE, N-CYCLOPENTYL-
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Phase 2CCC
Tislelizumab
BeiGene
Phase 1/2CCC
rc48-adc
BeiGene
Phase 1/2CCC
Ruxolitinib
National Health Research Institutes, Taiwan
Phase 1/2CC
Efineptakin Alfa
NeoImmuneTech
Phase 1CC

Same molecule, other indications

Pyrotinib is also rated in:

Non Small Cell Lung CancerDormant
BB
Indicative ·
70 / 100
View asset →
breast carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
Small Cell Lung CancerDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →